Lars Nieba
Chief Executive Officer at Engimmune Therapeutics AG
Net worth: 1 514 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Norbert Winkeljohann | M | 66 | 6 years | |
| Colleen Goggins | F | 68 | 7 years | |
| Ertharin Cousin | M | 67 | 5 years | |
| Wolfgang U. Nickl | M | 55 | 6 years | |
| Rodrigo Vazquez-Lombardi | M | - |
Engimmune Therapeutics AG
 Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | 3 years |
| Bent K. Jakobsen | M | - |
Engimmune Therapeutics AG
Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | 2 years |
| Hans Caspar von der Crone | M | 67 |
University of Zurich
| 27 years |
| Christian Maertin | M | - | 8 years | |
| Manuel Ammann | M | 54 |
University of St. Gallen
| 21 years |
| Thomas Hoffmann | M | 53 | 5 years | |
| Jürgen Eckhardt | M | 57 | 8 years | |
| Stefan Oelrich | M | 56 | 6 years | |
| Annalisa D’Andrea | F | - |
Engimmune Therapeutics AG
Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | 1 years |
| Brad Griffith | M | - | 8 years | |
| Gambillara Fonck Veronica | M | - |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Anette Waygood | M | - |
University of St. Gallen
| 12 years |
| Hartmut Klusik | M | 67 | 3 years | |
| Norbert W. Bischofberger | M | 68 | 7 years | |
| Reto Suter | M | 53 |
University of Zurich
| 8 years |
| Pablo Erat | M | 52 |
University of St. Gallen
| 4 years |
| Felix A. Zimmermann | M | 58 |
University of Freiburg
| 4 years |
| Herbert M. Heitmann | M | 61 | 3 years | |
| Dieter Weinand | M | 63 | 5 years | |
| Daniël M. Geiger | M | - |
University of St. Gallen
| 5 years |
| Lukas Weder | M | - |
University of St. Gallen
| 5 years |
| Michael Zahn | M | 61 |
University of Freiburg
| 5 years |
| Vanessa Frey | F | 44 |
University of St. Gallen
| 2 years |
| Judith Bischof | M | 50 |
University of Zurich
| 6 years |
| Petra Kronen | F | 59 | 37 years | |
| Johannes M. Dietsch | M | 62 | 16 years | |
| Daniel Schmucki | M | 56 |
University of Zurich
| 6 years |
| Silvio Inderbitzin | M | 59 |
University of Zurich
University of St. Gallen
| 7 years |
| Marcus Claessen | M | - |
University of St. Gallen
| 6 years |
| Søren Mouritsen | M | - |
Engimmune Therapeutics AG
Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | 2 years |
| Thomas Roland Meier | M | 61 |
University of Zurich
| 4 years |
| Andreas Hellmann | M | - |
University of St. Gallen
| 6 years |
| Ferdinand Niederhofer | M | - |
University of St. Gallen
| 4 years |
| Daniel von Stockar | M | - |
University of Zurich
| 3 years |
| Marcel Huber | M | - |
University of Zurich
| 6 years |
| Guido Koch | M | - |
University of St. Gallen
| 3 years |
| Martin Eisenring | M | - |
University of Zurich
| 3 years |
| Andreas Knecht | M | 55 |
University of Zurich
| 6 years |
| Alexander Ott | M | - |
University of St. Gallen
| 4 years |
| Christoph Daniel Hinder | M | - |
University of St. Gallen
| 5 years |
| Werner Lüscher | M | - |
University of Zurich
| 2 years |
| Marc Meier | M | - |
University of St. Gallen
| 3 years |
| André Odermatt | M | 64 |
University of Zurich
| 4 years |
| Ursula Nötzli | M | - |
University of St. Gallen
| 5 years |
| Hans Wicki | M | 60 |
University of Zurich
| 5 years |
| Marcel Dillier | M | - |
University of Zurich
| 5 years |
| Matthias Bulach | M | 48 |
University of St. Gallen
| 5 years |
| Philippe Weber | M | 59 |
University of Zurich
| 3 years |
| Johannes Reichel | M | 42 |
University of St. Gallen
| 3 years |
| Pius Grüter | M | - |
University of St. Gallen
| 4 years |
| Nic Dreckmann | M | 50 |
University of Zurich
| 4 years |
| Sven Schaltegger | M | - |
University of Zurich
| 7 years |
| Silvan Zehnder | M | - |
University of St. Gallen
| 4 years |
| Natalie Epp | F | - |
University of St. Gallen
| 3 years |
| Tobias Foster | M | 49 |
University of Zurich
| 4 years |
| David Enrico Tizzoni | M | 59 |
University of Zurich
| 7 years |
| Marco Probst | M | - |
University of Zurich
| 5 years |
| Gabrielle Nater-Bass | F | 56 |
University of Zurich
| 3 years |
| Jan Christopher Bruennler | M | - |
University of St. Gallen
| 5 years |
| Thomas Ogilvie | M | 48 |
University of St. Gallen
| 3 years |
| Wolfgang Weber | M | 57 |
University of Zurich
| 3 years |
| Ronald Beigl | M | - |
University of St. Gallen
| 2 years |
| Peter Lichtlen | M | 56 |
University of Zurich
| 4 years |
| Sascha Gruber | M | - |
University of St. Gallen
| 5 years |
| Giacomo Balzarini | M | 56 |
University of Zurich
| 4 years |
| Christian Hasler | M | - |
University of Zurich
| 5 years |
| Jochen Hennig | M | - |
University of St. Gallen
| 4 years |
| Thomas Schöber | M | - |
University of St. Gallen
| 1 years |
| Steffen Wieland | M | 55 |
University of St. Gallen
| 2 years |
| Mathias Schmid | M | 60 |
University of Zurich
| 3 years |
| Alexander Gut | M | 61 |
University of Zurich
| 3 years |
| Margret Suckale | F | 68 |
University of St. Gallen
| 3 years |
| Patrik Forrer | M | - |
University of Zurich
| 3 years |
| Sven Zimmermann | M | 53 |
University of Zurich
| 3 years |
| Michael Altorfer | M | - |
University of Zurich
| 3 years |
| Christian C. Wenger | M | 60 |
University of Zurich
| 3 years |
| Nicole Tschudi | F | 52 |
University of Zurich
| 5 years |
| Sonja Rossteuscher | F | 49 |
University of St. Gallen
| 2 years |
| Roger Meier-Rossi | M | - |
University of Zurich
| 3 years |
| Daniel Anders | M | 54 |
University of Zurich
| 4 years |
| Philippe Moser | M | - |
University of St. Gallen
| 4 years |
| David Klein | M | 47 |
University of St. Gallen
| 4 years |
| Marcus Dimpfel | M | 51 |
University of St. Gallen
| 3 years |
| Thies Rixen | M | - |
University of St. Gallen
| 2 years |
| Teodoro D. Cocca | M | 51 |
University of Zurich
| 4 years |
| Ranjit de Sousa | M | - |
University of St. Gallen
| 3 years |
| Philip Sauer | M | - |
University of St. Gallen
| 6 years |
| Igor Tadeusz Kuzniar | M | - |
University of St. Gallen
| 4 years |
| Andreas Schulthess | M | 54 |
University of Zurich
| 4 years |
| Christian Wiesendanger | M | 60 |
University of Zurich
| 4 years |
| Elisa Parisi-Capone | F | - |
University of Zurich
| 6 years |
| Silvano Maffeis | M | 57 |
University of Zurich
| 3 years |
| Markus Gygax | M | 62 |
University of St. Gallen
| 2 years |
| Thomas Oetterli | M | 55 |
University of Zurich
| 4 years |
| Christoph Tonini | M | 54 |
University of St. Gallen
| 2 years |
| Greg Michel | M | - |
University of St. Gallen
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 83 | 83.00% |
| Germany | 17 | 17.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lars Nieba
- Personal Network
